Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.
Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Posted inCardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.
Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis
Posted inDiabetes & Endocrinology news Oncology

Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis

A multicenter study in China demonstrates that radioactive iodine therapy may not significantly improve structural or biochemical response rates in T1-T2 stage papillary thyroid carcinoma with lymph node metastasis, highlighting the lymph node ratio as a more critical predictor of recurrence.
Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Posted inCardiology Diabetes & Endocrinology news

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesity, highlighting benefits beyond traditional major adverse cardiovascular events.
Posted inAnesthesiology Diabetes & Endocrinology news

European Perioperative Diabetes Care: Significant Practice Variation Impacts 30-Day Recovery Outcomes

The MOPED study of over 6,000 European patients reveals significant international variations in perioperative diabetes management. Findings demonstrate that higher preoperative HbA1c levels and practice inconsistencies are linked to fewer days at home within 30 days of surgery, highlighting an urgent need for clinical harmonization.
Posted inDiabetes & Endocrinology Internal Medicine news

Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups

A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to optimize performance in different populations.
Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile of dual GIP/GLP-1 agonism compared to established standards of care.
Planetary Health Diet and Cardiometabolic Risk Reduction in Women with Gestational Diabetes: An Evidence-Based Review
Posted inClinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news OB/GYN & Women's Health

Planetary Health Diet and Cardiometabolic Risk Reduction in Women with Gestational Diabetes: An Evidence-Based Review

This review synthesizes evidence linking adherence to the Planetary Health Diet with reduced risks of myocardial infarction, type 2 diabetes, and improved weight management in women post-gestational diabetes, highlighting BMI's mediating role.